What is Phantom Neuro?
Phantom Neuro is a future-driven neurotechnology enterprise dedicated to revolutionizing human-machine interaction. The company specializes in the development of the world's first minimally invasive muscle-machine interface, a breakthrough designed to provide seamless control for robotic prosthetic limbs and exoskeletons. By leveraging advanced neural signal processing, the firm aims to restore mobility and autonomy to individuals with limb loss or neurological impairments. Positioned at the intersection of medical device innovation and robotics, Phantom Neuro operates within a high-barrier-to-entry market, utilizing its academic roots to drive scientific rigor in its product development lifecycle.
How much funding has Phantom Neuro raised?
Phantom Neuro has raised a total of $28.3M across 3 funding rounds:
Other Financing Round
$3.3M
Other Financing Round
$6M
Other Financing Round
$19M
Other Financing Round (2022): $3.3M with participation from Breakout Ventures, Capital Factory companies, Draper Associates, Blackrock Neurotech, and LionBird Ventures
Other Financing Round (2022): $6M led by Time BioVentures, LionBird Ventures, Risk Return, and Draper Associates & Breakout Ventures
Other Financing Round (2025): $19M supported by E1 ventures, R-square RiskLab, Ottobock, METIS Innovative, Breakout Ventures, Time BioVentures, Draper & Associates, Actual Ventures, and LionBird
Key Investors in Phantom Neuro
Ottobock
A German family-owned medical technology leader founded in 1919, specializing in prosthetics, power wheelchairs, and advanced rehabilitation solutions.
Breakout Ventures
A venture capital firm focused on scaling scientific advancements and transformative technologies into category-defining companies.
Blackrock Neurotech
A specialized provider of precision electrode technology and neurotech expertise, enabling clinical solutions for Brain-Computer Interfaces.
What's next for Phantom Neuro?
With the recent influx of capital, Phantom Neuro is poised to accelerate its clinical development roadmap and expand its operational footprint. The company's strategic focus will likely shift toward securing regulatory milestones and refining its interface technology for broader commercial application. As the neurotechnology landscape matures, the firm is expected to leverage its partnerships with industry-leading medical technology investors to navigate the complexities of clinical trials and market entry. The focus remains on scaling its core technology to meet the growing demand for sophisticated, intuitive prosthetic solutions that significantly enhance patient quality of life.
See full Phantom Neuro company page
